Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

Abstract When breast cancer patients start to exhibit resistance to hormonal therapy or chemotherapy, the mTOR inhibitor everolimus can be considered as an alternative therapeutic agent. Everolimus can deregulate the PI3K/AKT/mTOR pathway and affect a range of cellular functions. In some patients, t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chun-Ting Kuo, Chen-Lin Chen, Chih-Chi Li, Guan-Syuan Huang, Wei-Yuan Ma, Wei-Fan Hsu, Ching-Hung Lin, Yen-Shen Lu, Andrew M. Wo
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/c7eb9d6b994340dfae24eaf48c223d35
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares